SyntekaBio Pushes AI Drug Discovery with 'DeepMatcher' 작성일 09-26 59 목록 <strong class="summary_view" data-translation="true">Sungkyunkwan Med School, Enbios Ink Drug Optimization Deals</strong> <div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> <section dmcf-sid="81MYmP6Fs8"> <p contents-hash="09cfe2a75890c2645452862fd2ec3a199fa3701fdb607e3a06895e080ed99f43" dmcf-pid="6tRGsQP3m4" dmcf-ptype="general"> [Kim Saemi, Edaily Reporter] SyntekaBio, Inc. is beginning to show tangible results from its proprietary artificial intelligence (AI) drug discovery platform, DeepMatcher. The company recently signed successive drug optimization contracts with Sungkyunkwan University School of Medicine and natural product-based new drug developer Enbios, signaling the full-fledged acceleration of AI-driven drug discovery achievements.</p> <figure class="figure_frm origin_fig" contents-hash="d99ed199402e462841887c40dff4d9d0bb3ca487300134377b7fbc0a84fef25c" dmcf-pid="PuLtSJdzrf" dmcf-ptype="figure"> <p class="link_figure"><img alt="SyntekaBio and Enbios sign partnership agreement at the Daejeon ABS Center on Sept. 25. (Source: SyntekaBio, Inc.)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202509/26/Edaily/20250926185552465jtjs.jpg" data-org-width="444" dmcf-mid="4Sc7HNaVs6" dmcf-mtype="image" height="auto" src="https://img1.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202509/26/Edaily/20250926185552465jtjs.jpg" width="658"></p> <figcaption class="txt_caption default_figure"> SyntekaBio and Enbios sign partnership agreement at the Daejeon ABS Center on Sept. 25. (Source: SyntekaBio, Inc.) </figcaption> </figure> <div contents-hash="2aa7906eda85b10d35ce7c70cd021a88297c3d4a0f4beadb5e82ee36ff2d6c37" dmcf-pid="Q7oFviJqwV" dmcf-ptype="general"> According to the company on the 26th, SyntekaBio signed a service contract on September 22 with Professor Dong-Ik Kim’s team at Sungkyunkwan University School of Medicine for “drug optimization using DeepMatcher.” Professor Kim’s team is carrying out the “anti-aging reversal project,” part of the Industrial Technology Alchemist Program overseen by the Korea Evaluation Institute of Industrial Technology under the Ministry of Trade, Industry and Energy. </div> <p contents-hash="d478b42ddc0dfb5afa44fd81d789813dfc0f95886a41c8d7f779d83e5b8eb86e" dmcf-pid="xzg3TniBm2" dmcf-ptype="general">The contract aims to enhance the efficacy of one candidate compound in the project by applying DeepMatcher and to identify new compounds. SyntekaBio plans to conduct research based on natural product-derived ingredients, including analyzing key residues in protein?compound binding, designing derivatives using DeepMatcher, and discovering novel compounds. The research is scheduled to continue through December 31.</p> <p contents-hash="9bc2ab7b1b616eae6e0b613750467b02bc50786c6a70c8cc64daa1a61964a9db" dmcf-pid="yEFaQ5Zws9" dmcf-ptype="general">Following that, on September 25 SyntekaBio signed a DeepMatcher service contract and a strategic partnership agreement with Enbios, a biotech specializing in natural product-based drug development.</p> <p contents-hash="6d31c77eee89cd2693d985ccce4ef2e2caf6bfb6b7608a567444250f3e287cca" dmcf-pid="WD3Nx15rmK" dmcf-ptype="general">The two companies will jointly optimize candidate compounds targeting cancer indications using DeepMatcher and generate new chemical entities. They also plan to secure joint intellectual property (IP) rights for newly discovered substances and pursue commercialization based on those rights.</p> <p contents-hash="174178a4cf179049df087a1e27b0d3b8801f6c407192e562a9e18db4170f6450" dmcf-pid="Yw0jMt1mDb" dmcf-ptype="general">A SyntekaBio official stated, “Unlike ordinary short-term service contracts, these agreements carry significance as strategic partnerships that could translate into long-term revenue. Based on DeepMatcher’s technological capabilities, we aim to deliver tangible and visible results in the drug development field.”</p> <p contents-hash="dca037365190769cd041a5c9385f62960069d6a30ee08112deb5fe97ce5cf9bc" dmcf-pid="GrpARFtsEB" dmcf-ptype="general">김새미 (bird@edaily.co.kr) </p> </section> </div> <p class="" data-translation="true">Copyright © 이데일리. 무단전재 및 재배포 금지.</p> 관련자료 이전 퍼스트 디센던트, 日 게이머들 시선 제대로 사로잡다 09-26 다음 ‘뮤뱅’ 머쉬베놈, 신빠람 이박사와 함께 음방 데뷔→흥 멈출 수 없는 ‘돌림판’ 퍼포먼스 09-26 댓글 0 등록된 댓글이 없습니다. 로그인한 회원만 댓글 등록이 가능합니다.
